One-stop mRNA Therapeutics Development

Online inquiry

  • Email:
  • One-stop mRNA Therapeutics Development

    The novel messenger ribonucleic acid (mRNA) therapeutics strategies have aroused great attention in many clinical settings, such as cancer treatment. To meet the challenging requirements, Creative Biolabs has built a team of experienced scientists with facilities and processes designed specifically to provide the best strategy and protocols customized to mRNA-based services. We have accomplished many projects and have delivered numerous novel or validated mRNA therapeutics in a range of therapeutic areas.

    Introduction to mRNA Therapeutics

    mRNA is usually created during the process of in vitro transcription (IVT) of various linearized pDNAs or PCR products. It is composed of a promoter domain (5' cap), 5' and 3' untranslated regions (UTRs), an open reading frame (ORF), as well as a poly(A) sequence. In general, the modification of UTR and ORF sequences can strongly improve the efficiency of mRNA synthesis. Meanwhile, the poly(A) sequence and 5' cap play an important role in mediating the process of mRNA translation. IVT mRNA is capable of regulating the activation of innate immunity. Furthermore, pilot studies have shown that IVT mRNA delivery can be achieved by both in vitro and in vivo transfection assays. The results have indicated that these methods can deliver enough target cells to trigger strong immune responses against various human diseases, such as malignant tumors.

    Schematic representation of synthetic mRNA and its structural features. Fig.1 Schematic representation of synthetic mRNA and its structural features. (Zhong, 2018)

    Our Platform for mRNA Therapeutics

    Recently, mRNA therapeutics has been regarded as a huge milestone in personalized treatment. In particular, mRNA therapeutics can produce a new class of therapeutic proteins that highly specific for target disease types. Many large scales of clinical trials have been conducted for evaluating the safety and efficacy of mRNA therapeutics in different disease models. Moreover, advances in mRNA technology have facilitated the development of IVT mRNA for a wider range of disease treatments.

    Basing on the requirement of mRNA study in drug discovery, Creative Biolabs has generated a one-stop mRNA therapeutics development platform to assist in all areas of mRNA-based projects, ranging from the design and production of mRNA molecules, mRNA biology, mRNA formulation and delivery, mRNA immunogenicity evaluation, to protein engineering. Till now, a wide variety of therapeutic areas have been exclusively studied by using a panel of mRNA-based technologies. For instance, we have also established several strategies, such as reverse transcription PCR (qRT-PCR) and branched DNA, for analyzing engineered mRNA therapeutics. Furthermore, we provide a series of safety and efficacy assessment services for mRNA therapeutics, which is essential to reduce the cost and improve the success rate of drug development.

    Potential therapeutic applications of IVT mRNA. Fig.2 Potential therapeutic applications of IVT mRNA. (Sahin, 2014)

    Chief Services

    Equipped with state-of-the-art facilities and highly experienced staff, Creative Biolabs has integrated high-quality mRNA-based services which are based in America and span the entire development chain from discovery to commercialization, including but not limited to:

    With years of operational experience, Creative Biolabs can provide state-of-the-art services for any mRNA-based project with qualitative measurements. Our scientists specialized in mRNA therapeutics will work with you to develop a most appropriate strategy that will offer the most meaningful data for your research. Now, we have developed efficient protocols for various mRNA-based assays. And we can also conduct novel mRNA discovery studies in various kinds of aspects. If you are interested in our services, please feel free to contact us for more information.

    Reference

    1. Zhong, Z.; et al. mRNA therapeutics deliver a hopeful message. Nano today. 2018, 23: 16-39.
    2. Sahin, U.; et al. mRNA-based therapeutics-developing a new class of drugs. Nature reviews Drug discovery. 2014, 13(10): 759.
    For Research Use Only.